2022
DOI: 10.1182/blood-2022-168568
|View full text |Cite
|
Sign up to set email alerts
|

Blinatumomab in Combination with an Intensive Pediatric Protocol Results in High Rates of Day 79 MRD Negativity in Adolescent and Young Adult Acute Lymphoblastic Leukemia - Preliminary Results of the Australasian Leukaemia and Lymphoma Group (ALLG) ALL09 "Sublime” Study

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
1

Citation Types

0
1
0

Year Published

2024
2024
2024
2024

Publication Types

Select...
1

Relationship

0
1

Authors

Journals

citations
Cited by 1 publication
(1 citation statement)
references
References 0 publications
0
1
0
Order By: Relevance
“…A white male in his forties with Crohn’s disease and Ankylosing Spondylitis treated with Adalimumab was diagnosed with acute lymphoblastic leukaemia and treated with induction prednisolone, methotrextate, danorubicin, vincristine, pegaspargase with Blinatumomab consolidation (ALLG ALL09 SuBliME trial) 8 followed by reduced-intensity fludarabine-melphalan conditioned matched unrelated donor (MUD) SCT. GvHD prophylaxis was with cyclophosphamide and cyclosporin, later transitioned to mycophenolate mofetil.…”
Section: Patientmentioning
confidence: 99%
“…A white male in his forties with Crohn’s disease and Ankylosing Spondylitis treated with Adalimumab was diagnosed with acute lymphoblastic leukaemia and treated with induction prednisolone, methotrextate, danorubicin, vincristine, pegaspargase with Blinatumomab consolidation (ALLG ALL09 SuBliME trial) 8 followed by reduced-intensity fludarabine-melphalan conditioned matched unrelated donor (MUD) SCT. GvHD prophylaxis was with cyclophosphamide and cyclosporin, later transitioned to mycophenolate mofetil.…”
Section: Patientmentioning
confidence: 99%